Literature DB >> 19465903

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

Bo Han1, Rohit Mehra, Khalid Suleman, Scott A Tomlins, Lei Wang, Nishi Singhal, Katherine A Linetzky, Nallasivam Palanisamy, Ming Zhou, Arul M Chinnaiyan, Rajal B Shah.   

Abstract

Histologic variants of prostate carcinoma account for 5-10% of the disease and are typically seen in association with conventional acinar carcinoma. These variants often differ from the latter in clinical, immunophenotypic, and biologic potential. Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas. However, the frequency and significance of this critical molecular event is unknown in the histologic variants of prostate carcinoma. Here, we used break-apart fluorescence in situ hybridization to assess TMPRSS2 and ETS aberrations in a series of select histologic variants: foamy gland carcinoma (N=17), ductal adenocarcinoma (N=18), mucinous carcinoma (N=18), and small cell carcinoma (N=7). A histologic variation of acinar adenocarcinoma, demonstrating glomeruloid morphology (N=9), was also investigated. Overall, 55% of histologic variant or variation morphologies demonstrated ETS aberrations (ERG in 54% and ETV1 in 1%). TMPRSS2:ERG fusion was identified in 83% (15/18), 71% (5/7), 50% (9/18), 33% (3/9), and 29% (5/17) of mucinous, small cell, ductal, glomeruloid, and foamy gland prostate carcinomas, respectively. Previously, we reported that 100% of androgen-independent metastatic prostate carcinomas harboring TMPRSS2:ERG gene fusion were associated with interstitial deletion (Edel). Interestingly, ERG rearrangement in small cell carcinomas occurred exclusively through Edel, supporting the notion that TMPRSS2:ERG with Edel is an aggressive molecular subtype. SPINK1, a biomarker expressed exclusively in a subset of ETS negative prostate carcinomas, was expressed in 6% of ETS negative histologic variants, specifically in ductal adenocarcinoma. Notably, 88% (43/49) variant morphologies in this cohort showed concordance of TMPRSS2:ERG fusion with associated conventional acinar type, suggesting that variant morphology is clonally related to the latter. Overall, our data provide insight into the origin, molecular mechanism, and phenotypic association of ETS fusions in histologic variants of prostate carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465903      PMCID: PMC2760291          DOI: 10.1038/modpathol.2009.79

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  31 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  Combined small-cell carcinoma of the stomach: p53 and K-ras gene mutational analysis supports a monoclonal origin of three histological components.

Authors:  Bo Han; Ichiro Mori; Xiaojuan Wang; Misa Nakamura; Yasushi Nakamura; Kennichi Kakudo
Journal:  Int J Exp Pathol       Date:  2005-08       Impact factor: 1.925

3.  The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.

Authors:  J V Melo
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

Review 4.  Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance.

Authors:  T L Randolph; M B Amin; J Y Ro; A G Ayala
Journal:  Mod Pathol       Date:  1997-06       Impact factor: 7.842

Review 5.  The pathology of familial breast cancer: Morphological aspects.

Authors:  S R Lakhani
Journal:  Breast Cancer Res       Date:  1999-10-27       Impact factor: 6.466

6.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Authors:  Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

7.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.

Authors:  Kristiina Iljin; Maija Wolf; Henrik Edgren; Santosh Gupta; Sami Kilpinen; Rolf I Skotheim; Mari Peltola; Frank Smit; Gerald Verhaegh; Jack Schalken; Matthias Nees; Olli Kallioniemi
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

Review 9.  Unusual subtypes of prostate cancer.

Authors:  David J Grignon
Journal:  Mod Pathol       Date:  2004-03       Impact factor: 7.842

10.  A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.

Authors:  Nikita Makretsov; May He; Malcolm Hayes; Stephen Chia; Doug E Horsman; Poul H B Sorensen; David G Huntsman
Journal:  Genes Chromosomes Cancer       Date:  2004-06       Impact factor: 5.006

View more
  26 in total

1.  ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Authors:  Sean R Williamson; Shaobo Zhang; Jorge L Yao; Jiaoti Huang; Antonio Lopez-Beltran; Steven Shen; Adeboye O Osunkoya; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

2.  TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

Authors:  Charles C Guo; Jane Y Dancer; Yan Wang; Ana Aparicio; Nora M Navone; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2010-10-30       Impact factor: 3.466

Review 3.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

4.  TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens.

Authors:  Ömer Yılmaz; Ufuk Berber; Sezgin Okçelik; Hasan Soydan; Ferhat Ateş; Kenan Karademir
Journal:  Turk J Urol       Date:  2016-06

5.  Potential for targeted therapy in prostate cancers with ERG abnormalities.

Authors:  Sean R Williamson; Liang Cheng
Journal:  Asian J Androl       Date:  2011-07-25       Impact factor: 3.285

Review 6.  Emerging Variants of Castration-Resistant Prostate Cancer.

Authors:  Panagiotis J Vlachostergios; Loredana Puca; Himisha Beltran
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

7.  Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Authors:  Marc Gillard; Justin Lack; Andrea Pontier; Divya Gandla; David Hatcher; Adam G Sowalsky; Jose Rodriguez-Nieves; Donald Vander Griend; Gladell Paner; David VanderWeele
Journal:  Eur Urol Focus       Date:  2017-12-08

8.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.

Authors:  David S Rickman; Ying-Bei Chen; Samprit Banerjee; Yihang Pan; Jindan Yu; Terry Vuong; Sven Perner; Christopher J Lafargue; Kirsten D Mertz; Sunita R Setlur; Kanishka Sircar; Arul M Chinnaiyan; Tarek A Bismar; Mark A Rubin; Francesca Demichelis
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

9.  TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Authors:  Samson W Fine; Anuradha Gopalan; Margaret A Leversha; Hikmat A Al-Ahmadie; Satish K Tickoo; Qin Zhou; Jaya M Satagopan; Peter T Scardino; William L Gerald; Victor E Reuter
Journal:  Mod Pathol       Date:  2010-06-18       Impact factor: 7.842

10.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Authors:  Juan Miguel Mosquera; Himisha Beltran; Kyung Park; Theresa Y MacDonald; Brian D Robinson; Scott T Tagawa; Sven Perner; Tarek A Bismar; Andreas Erbersdobler; Rajiv Dhir; Joel B Nelson; David M Nanus; Mark A Rubin
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.